Elevated expression of TPL2 in BRAF V600E‐mutated melanoma cells is known to confer resistance to BRAF inhibitors, and TPL2 expression is higher in patients with relapse after BRAF inhibitor therapy.28 The gene discussed is MAP3K8; the disease is melanoma.